PARP Inhibition and Ovarian Cancer

PARP Inhibition and Ovarian Cancer

Leading the Field in Exploiting DNA Repair as a Therapeutic Target

Not a member of My prIME? Join now for instant access.

Meeting Overview

Enhance your understanding of the use of PARP inhibitors in ovarian cancer at this interactive satellite symposium. A variety of topics will be discussed, including DNA repair and PARP inhibition, use of PARP inhibitors in various settings, future directions, and practical considerations for PARP inhibitor therapy in the clinic.

This symposium is an official symposium of the 20th International Meeting of the European Society of Gynaecological Oncology.

Date and Location

Monday, 6 November 2017
16.00 – 17.00

Hall C
Austria Center
Bruno-Kreisky-Platz 1
Vienna, Austria



Monday, 6 November 2017
16.00 – 17.00



Vienna, Austria



1.0 AMA PRA Category 1 Credit

16.00 Welcome and introduction
Nicoletta Colombo, MD
16.02 Introductory quiz
Nicoletta Colombo, MD
16.05 Everything a clinician needs to know about DNA repair and PARP inhibition
Thomas Helleday, PhD
16.20 A new string to the bow in the treatment of advanced ovarian cancer
Bradley J. Monk, MD, FACS, FACOG
16.35 Clinical application of PARP inhibitors: Proactive management of adverse events
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
16.45 Q & A and faculty discussion
16.53 PARP inhibition and ovarian cancer: Have we convinced you?
Nicoletta Colombo, MD
16.58 prIME Points™
Nicoletta Colombo, MD
17.00 Adjourn


  • Nicoletta Colombo, MD, PhDUniversity of Milan–Bicocca
    European Institute of Oncology
    Milan, Italy
  • Faculty

  • Thomas Helleday, PhDKarolinska Institute
    Stockholm, Sweden
  • Rebecca Kristeleit, MD, PhDUCL Cancer Institute
    University College London
    London, United Kingdom
  • Bradley J. Monk, MD, FACS, FACOGArizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix
    Creighton University School of Medicine at St Joseph's Hospital
    Phoenix, Arizona, United States

This live educational activity is designed for oncologists, gynecologists, and other healthcare professionals interested and/or involved in the use of PARP inhibitors for the treatment of patients with ovarian cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe current and emerging biomarkers that assess genomic instability and evaluate defects in DNA repair
  • Evaluate emerging clinical data and ongoing trials involving PARP inhibition for patients with BRCA 1/2 mutant and wildtype ovarian cancer
  • Assess the adverse events associated with PARP inhibition for ovarian cancer and how best to ensure long-term adherence to PARP inhibitors

This educational activity is supported by a grant from Clovis Oncology, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Good CME Practice


This activity is provided by prIME Oncology.

Sunshine Act/EFPIA

prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.